CAJ | 학술논문

目的：探讨吉西他滨与顺铂联合应用治疗48例耐药晚期胃癌的疗效；分析吉西他滨与顺铂联合应用的治疗价值。方法：选取2012年3月一2014年10月在我院治疗的耐药晚期胃癌患者共48例，随机分为观察组24例(应用吉西他滨与顺铂联用方案)和对照组24例(应用卡培他滨与顺铂联合方案)，回顾性分析两组患者的临床效果，结果观察组总缓解率为58.10%；对照组总缓解率为52.6%，P>0.05，无显著差异；观察组不良反应发生率为17.60%。对照组不良反应发生率为40.20%，经统计分析，P<0.05，差异存在显著性。结论：吉西他滨与顺铂联合应用是耐药晚期胃癌的较为安全有效的化疗方案。
목적：탐토길서타빈여순박연합응용치료48례내약만기위암적료효；분석길서타빈여순박연합응용적치료개치。방법：선취2012년3월일2014년10월재아원치료적내약만기위암환자공48례，수궤분위관찰조24례(응용길서타빈여순박련용방안)화대조조24례(응용잡배타빈여순박연합방안)，회고성분석량조환자적림상효과，결과관찰조총완해솔위58.10%；대조조총완해솔위52.6%，P>0.05，무현저차이；관찰조불량반응발생솔위17.60%。대조조불량반응발생솔위40.20%，경통계분석，P<0.05，차이존재현저성。결론：길서타빈여순박연합응용시내약만기위암적교위안전유효적화료방안。
Objective To explore the clinical curative effect of gemcitabine combined with cisplatin on tolerance advanced cancer of stomach .Analysis the curation value of gemcitabine combined with cisplatin Methods Choose 48 patients with advanced gastric cancer who were treated in our hospital from March 2014 to October 2014.They were randomly divided into observation group,24 cases(Using the scheme of gemcitabine and cisplatin combination),and the contrast group,24 cases (Appling the scheme of capecitabine and cisplatin combination).The clinical effects of the two groups were retrospectively analyzed. Results The total catabatic rate was 58.1%in the observation group ,and the total catabatic rate was 52.6%in the contrast group (P>0.05).There were no significant differences. The incidence of adverse reaction was 17.6%in the observation group ,and in the contrast group ,it was 40.2%after statistical analysis(P<0.05).There were significant differences. Conclusion The united application of gemcitabine and cisplatin is relatively safe and effective chemotherapy scheme on tolerance advanced cancer of stomach.